Intas Pharmaceuticals Secures Global Pegfilgrastim Leadership
Ahmedabad, August 7: Intas Pharmaceuticals has significantly strengthened its global presence in the pharmaceutical sector. The company, along with its international Accord subsidiaries, has acquired UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc. This acquisition solidifies Intas’ position as a leading global supplier of pegfilgrastim.
This strategic move underscores Intas’ commitment to expanding its portfolio of biosimilars. The acquisition of UDENYCA®, a biosimilar pegfilgrastim, broadens their reach in the oncology market.
The deal significantly enhances Intas’ global footprint and reinforces its commitment to providing affordable, high-quality medications. This development is expected to benefit patients worldwide, particularly in emerging markets.
The successful acquisition highlights India’s growing prowess in the biosimilar arena. It positions Intas as a key player in the global healthcare landscape, impacting access to life-saving medications for millions.
